# OnCo record paper-impower110-atezolizumab-pd-l1-nejm-2020 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-impower110-atezolizumab-pd-l1-nejm-2020/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-impower110-atezolizumab-pd-l1-nejm-2020" ;
  schema:name "IMpower110: atezolizumab for first-line treatment of PD-L1-selected patients with non-small-cell lung cancer"@en ;
  schema:description "In patients whose lung cancer had the highest levels of the PD-L1 protein and no targetable mutation, an immunotherapy drug given alone added about seven months of life compared with chemotherapy."@en ;
  schema:url <https://onco.cc/key-papers/paper-impower110-atezolizumab-pd-l1-nejm-2020/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa1917346>, <https://pubmed.ncbi.nlm.nih.gov/32997907/> ;
  schema:sameAs <https://doi.org/10.1056/NEJMoa1917346> ;
  schema:datePublished "2020"^^xsd:gYear ;
  schema:author "Herbst RS, Giaccone G, de Marinis F, et al." ;
  onco:related <https://onco.cc/biomarkers/pd-l1-tc-score/>, <https://onco.cc/biomarkers/pd-l1-ic-score/>, <https://onco.cc/biomarkers/tmb-high/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/histopathology-ihc/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/ventana-pd-l1-sp142/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/> ;
  onco:terms <https://onco.cc/terms/ihc/>, <https://onco.cc/terms/tmb/> ;
  onco:people <https://onco.cc/people/roy-herbst/> ;
  onco:journals <https://onco.cc/journals/nejm/> .